Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803789 | 0.87 | GLA (0.45) | MAPTPOLBGLACRHBPCRHR2 | |
| SCHEMBL3580938 | 0.84 | MAPT (0.46) | MAPTPOLBGLACRHBPCRHR2 | |
| SCHEMBL8771567 | 0.84 | KMT2A (0.50) | MAPTPOLBGLACRHBPCRHR2 | |
| SCHEMBL13838448 | 0.84 | GLA (0.43) | MAPTPOLBGLACRHBPCRHR2 | |
| SCHEMBL23147201 | 0.83 | MAPT (0.45) | MAPTPOLBGLACRHBPCRHR2 | |
| SCHEMBL20568542 | 0.81 | ALDH1A1 (0.49) | MAPTPOLBGLACRHBPCRHR2 | |
| SCHEMBL30468543 | 0.79 | ALDH1A1 (0.47) | MAPTPOLBCRHBPCRHR2L3MBTL1 | |
| SCHEMBL1621780 | 0.79 | ALDH1A1 (0.47) | MAPTPOLBCRHBPCRHR2L3MBTL1 | |
| SCHEMBL16522671 | 0.77 | KMT2A (0.47) | MAPTPOLBGLACRHBPCRHR2 | |
| SCHEMBL27251740 | 0.77 | MEN1 (0.39) | MAPTPOLBL3MBTL1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20190077814-A1 | BORON-CONTAINING SMALL MOLECULES | GATES FOUNDATION | 2019-03-14 | — | — | US | disclosed |
| EP-3423065-A1 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | PRCL Research Inc. (CA) | 2017-08-17 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604978-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| EP-2704701-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012151355-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171446-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | MAPT 989/4885POLB 4408/4885GLA 223/4885 |
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
| US-20190077814-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BTD | MAPT 2516/4885POLB 337/4885GLA 905/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
| US-20170231984-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | MAPT 989/4885POLB 4408/4885GLA 223/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885POLB 3098/4885GLA 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.